Table 2—

Effects on laboratory parameters of increasing doses of candesartan in 23 type 2 diabetic patients with nephropathy

ParameterPlaceboCandesartan dose
8 mg16 mg32 mg
Renin (mU/l)*12 (9–16)40 (24–65)49 (31–74)50 (27–84)
Ang II (pmol/l)*8 (6–10)18 (11–27)17 (12–24)19 (11–29)
Aldosterone (pmol/l)*127 (98–181)112 (74–165)108 (73–162)94 (69–130)
Serum potassium (mmol/l)4.1 ± 0.14.2 ± 0.14.2 ± 0.14.4 ± 0.1
Serum cholesterol (mmol/l)5.6 ± 0.25.5 ± 0.25.3 ± 0.25.6 ± 0.3
HbA1c (%)8.4 ± 0.38.4 ± 0.38.5 ± 0.28.4 ± 0.2
Hemoglobin (mmol/l)8.6 ± 0.28.3 ± 0.28.2 ± 0.28.2 ± 0.2
Protein intake (g/kg/24-h)1.0 ± 0.061.0 ± 0.060.9 ± 0.050.9 ± 0.05
Urinary sodium excretion (mmol/24-h)219 ± 20213 ± 12205 ± 19211 ± 17
  • Data are means ± SEM.

  • *

    * Geometric mean (95% CI);

  • P < 0.05 versus placebo.